Steven I. Park
Experienced in Lymphofollicular Hyperplasia

Dr. Steven I. Park

Hematology | Oncology
100 Medical Park Drive, NE, Suite 110, 
Concord, NC 
On Staff At
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Experienced in Lymphofollicular Hyperplasia
100 Medical Park Drive, NE, Suite 110, 
Concord, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Steven Park is a Hematologist and an Oncologist in Concord, North Carolina. Dr. Park is rated as an Experienced provider by MediFind in the treatment of Lymphofollicular Hyperplasia. His top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Park is currently accepting new patients.

His clinical research consists of co-authoring 59 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Lymphofollicular Hyperplasia.

Graduate Institution
University Of California
Residency
University of Washington
Specialties
Hematology
Oncology
Licenses
Internal Medicine in NC
Board Certifications
American Board Of Internal Medicine, Medical Oncology
Fellowships
University of Washington
Hospital Affiliations
Carolinas Medical Center-Northeast
Carolinas Medical Center/behav Health
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Geisinger
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

Atrium Health Levine Cancer Institute
100 Medical Park Drive, NE, Suite 110, Concord, NC 28025
Other Locations
Atrium Health Levine Cancer Institute
1021 Morehead Medical Drive, Charlotte, NC 28204

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

Phase Ib/II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Hodgkin's Lymphoma and CD30+ Non-Hodgkin's Lymphoma
Phase Ib/II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Hodgkin's Lymphoma and CD30+ Non-Hodgkin's Lymphoma
Enrollment Status: Recruiting
Publish Date: October 14, 2025
Intervention Type: Biological
Study Drug: ATLCAR.CD30 cells
Study Phase: Phase 1/Phase 2
A Phase II Trial of PET-Directed Therapy Using AVD (Doxorubicin, Vinblastine, and Dacarbazine) Plus Brentuximab Vedotin Induction Chemotherapy, With or Without Brentuximab Vedotin Plus Nivolumab, Followed by Nivolumab Consolidation for Patients With Previously Untreated Non-Bulky Limited Stage Hodgkin Lymphoma
A Phase II Trial of PET-Directed Therapy Using AVD (Doxorubicin, Vinblastine, and Dacarbazine) Plus Brentuximab Vedotin Induction Chemotherapy, With or Without Brentuximab Vedotin Plus Nivolumab, Followed by Nivolumab Consolidation for Patients With Previously Untreated Non-Bulky Limited Stage Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: October 03, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Nivolumab, Vinblastine
Study Phase: Phase 2
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Prednisone, Rituximab, Vincristine Sulfate
Study Phase: Phase 2
A Phase 1B Trial Nivolumab Consolidation Following Completion of High-Dose Methotrexate Containing Induction Chemotherapy in Older (≥ 65) Patients With Primary CNS Lymphoma
A Phase 1B Trial Nivolumab Consolidation Following Completion of High-Dose Methotrexate Containing Induction Chemotherapy in Older (≥ 65) Patients With Primary CNS Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: July 09, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase I Trial of Ibrutinib Plus PD 0332991 (Palbociclib) in Patients With Previously Treated Mantle Cell Lymphoma
A Phase I Trial of Ibrutinib Plus PD 0332991 (Palbociclib) in Patients With Previously Treated Mantle Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: June 27, 2025
Intervention Type: Drug, Other
Study Drugs: Ibrutinib, Palbociclib
Study Phase: Phase 1
Phase I Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Prevention of Relapse of CD30+ Lymphomas After High Dose Therapy and Autologous Stem Transplantation (ATLAS)
Phase I Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Prevention of Relapse of CD30+ Lymphomas After High Dose Therapy and Autologous Stem Transplantation (ATLAS)
Enrollment Status: Active_not_recruiting
Publish Date: May 15, 2025
Intervention Type: Drug
Study Drug: Anti-CD30 CAR-T Cells
Study Phase: Phase 1
A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Enrollment Status: Completed
Publish Date: March 07, 2025
Intervention Type: Drug
Study Drug: Duvelisib
Study Phase: Phase 2
A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)
A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)
Enrollment Status: Active_not_recruiting
Publish Date: November 06, 2024
Intervention Type: Other, Drug, Biological
Study Drugs: Bleomycin, Brentuximab, Dacarbazine, Doxorubicin, Nivolumab, Vinblastine
Study Phase: Phase 2
Phase 1/2 Study of TAK-981 in Combination With Rituximab in Patients With Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
Phase 1/2 Study of TAK-981 in Combination With Rituximab in Patients With Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
Enrollment Status: Terminated
Publish Date: June 14, 2024
Intervention Type: Drug
Study Drugs: TAK-981, Rituximab
Study Phase: Phase 1/Phase 2
LCCC 1115: A Pilot Feasibility Trial of Induction Chemotherapy With ABVD Followed by Brentuximab Vedotin (SGN-35) Consolidation in Patients With Previously Untreated Non-Bulky Stage I or II Hodgkin Lymphoma (HL)
LCCC 1115: A Pilot Feasibility Trial of Induction Chemotherapy With ABVD Followed by Brentuximab Vedotin (SGN-35) Consolidation in Patients With Previously Untreated Non-Bulky Stage I or II Hodgkin Lymphoma (HL)
Enrollment Status: Completed
Publish Date: December 07, 2021
Intervention Type: Drug
Study Drugs: Brentuximab, Doxorubicin, Bleomycin, Dacarbazine
Study Phase: Not Applicable
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies
Enrollment Status: Terminated
Publish Date: November 19, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Open-Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (19A+RICE) Chemotherapy vs. RICE in the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Candidates for Autologous Stem Cell Transplant
A Randomized, Open-Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (19A+RICE) Chemotherapy vs. RICE in the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Candidates for Autologous Stem Cell Transplant
Enrollment Status: Terminated
Publish Date: May 17, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
Enrollment Status: Completed
Publish Date: April 19, 2018
Intervention Type: Drug
Study Phase: Phase 1
A Phase I/Ib Study of Alisertib Plus R-EPOCH for Treatment of Myc-Positive Aggressive B-Cell Lymphomas
A Phase I/Ib Study of Alisertib Plus R-EPOCH for Treatment of Myc-Positive Aggressive B-Cell Lymphomas
Enrollment Status: Terminated
Publish Date: November 20, 2017
Intervention Type: Drug
Study Phase: Phase 1
A Randomized, Wait-list Controlled Clinical Trial: the Effect of a Physical Activity Program on Fatigue After Potentially Curative Chemotherapy Among Cancer Survivors Age 65 or Older -- PACT (Physical Activity After Chemotherapy)
A Randomized, Wait-list Controlled Clinical Trial: the Effect of a Physical Activity Program on Fatigue After Potentially Curative Chemotherapy Among Cancer Survivors Age 65 or Older -- PACT (Physical Activity After Chemotherapy)
Enrollment Status: Completed
Publish Date: September 12, 2017
Intervention Type: Behavioral
Study Phase: Not Applicable
View 14 Less Clinical Trials

59 Total Publications

Evaluation of the Impact of Monitoring for Tumor Lysis During Venetoclax Ramp-Up in Chronic Lymphocytic Leukemia in Routine Clinical Practice.
Evaluation of the Impact of Monitoring for Tumor Lysis During Venetoclax Ramp-Up in Chronic Lymphocytic Leukemia in Routine Clinical Practice.
Journal: JCO oncology practice
Published: November 18, 2024
Similar Doctors
Raghava R. Induru
Distinguished in Lymphofollicular Hyperplasia
Dr. Raghava R. Induru
Hematology | Oncology
Distinguished in Lymphofollicular Hyperplasia
Dr. Raghava R. Induru
Hematology | Oncology

Atrium Health Levine Cancer Institute, A Facility Of Carolinas Medical Center

945-B N. 5th St., 
Albemarle, NC 
 (23.2 miles away)
980-323-7790
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Raghava Induru is a Hematologist and an Oncologist in Albemarle, North Carolina. Dr. Induru is rated as a Distinguished provider by MediFind in the treatment of Lymphofollicular Hyperplasia. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), and Chronic Lymphocytic Leukemia (CLL). Dr. Induru is currently accepting new patients.

Distinguished in Lymphofollicular Hyperplasia
Dr. Mihaela A. Vatca
Hematology Oncology | Hematology | Oncology
Distinguished in Lymphofollicular Hyperplasia
Dr. Mihaela A. Vatca
Hematology Oncology | Hematology | Oncology

Wake Forest University Health Sciences

Medical Ctr Blvd, 
Winston Salem, NC 
 (48.7 miles away)
336-716-2734
Languages Spoken:
English, Romanian
See accepted insurances
Accepting New Patients

Mihaela Vatca is a Hematologist Oncology specialist and a Hematologist in Winston Salem, North Carolina. Dr. Vatca is rated as a Distinguished provider by MediFind in the treatment of Lymphofollicular Hyperplasia. Her top areas of expertise are Lymphofollicular Hyperplasia, Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma, and Lung Cancer. Dr. Vatca is currently accepting new patients.

Kevin Patel
Advanced in Lymphofollicular Hyperplasia
Dr. Kevin Patel
Oncology | Hematology
Advanced in Lymphofollicular Hyperplasia
Dr. Kevin Patel
Oncology | Hematology

Novant Health Cancer Institute - Elizabeth (Gastrointestinal & Hepatobiliary Cancer)

125 Queens Road, Suite 430, 
Charlotte, NC 
 (20.0 miles away)
980-302-6300
Experience:
20+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kevin Patel is a Hematologist and an Oncologist in Charlotte, North Carolina. Dr. Patel has been practicing medicine for over 20 years and is rated as a Distinguished provider by MediFind in the treatment of Lymphofollicular Hyperplasia. His top areas of expertise are Monoclonal Gammopathy of Undetermined Significance (MGUS), Schnitzler Syndrome, Lung Cancer, Pleuropulmonary Blastoma, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Park's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 10 Advanced Conditions
View All 14 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile